Last reviewed · How we verify

Suzan A Rattan — Portfolio Competitive Intelligence Brief

Suzan A Rattan pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Intracameral Moxifloxacin 0.1% Intracameral Moxifloxacin 0.1% marketed Fluoroquinolone antibiotic Bacterial DNA gyrase and topoisomerase IV Ophthalmology / Infectious Disease

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Bayer · 1 shared drug class
  2. Bayer AG · 1 shared drug class
  3. Carolina Eyecare Physicians, LLC · 1 shared drug class
  4. Connect Biopharma Australia Pty Ltd · 1 shared drug class
  5. Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · 1 shared drug class
  6. Daewon Pharmaceutical Co., Ltd. · 1 shared drug class
  7. Fundacion Clinic per a la Recerca Biomédica · 1 shared drug class
  8. Allergan · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Suzan A Rattan:

Cite this brief

Drug Landscape (2026). Suzan A Rattan — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/suzan-a-rattan. Accessed 2026-05-16.

Related